RecruitingPhase 4NCT06072807

Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer

Brain [18F]-FES PET/CT in the Diagnosis, Treatment Planning and Response Assessment of Brain Metastases in Patients With Estrogen-Receptor Positive Breast Cancer

Sponsor

Weill Medical College of Cornell University

Enrollment

20 participants

Start Date

Dec 27, 2023

Study Type

INTERVENTIONAL

Conditions

Breast Cancer Brain Metastases

Summary

The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases. Patients will undergo MRI of the brain and FDG PET/CT brain as part of standard of care for radiation treatment planning. An additional 18F-FES PET/CT brain scan will be completed before this standard of care radiation treatment. Patients will be followed prospectively with clinical and MRI assessments per standard-of-care for a total of 12 months. Study Population: Patients with ER-positive breast cancer with biopsy proven or suspected new or recurrent brain metastases (based on standard of care MRI) planned for radiation treatment of brain lesions.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study uses a special PET scan with an estrogen-based tracer (called FES) to image brain metastases in women with estrogen receptor-positive (ER+) breast cancer. Researchers want to see whether this scan can help identify which brain tumors are likely to respond to hormone-based therapies. **You may be eligible if...** - You have ER+ breast cancer confirmed by biopsy - You have new or recurring brain metastases (confirmed or suspected by MRI) - You are 18 or older in good general health (ECOG 0–1) - You are planned for radiation therapy for your brain metastases - You have stopped taking ER-modifying drugs for the required washout period **You may NOT be eligible if...** - You are pregnant - You have an allergy to the FES imaging agent - You are unable to undergo standard of care Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTBrain Imaging with 18F-FES

Using 18F-FES radiotracer in PET/CT scan to evaluate brain metastases in ER positive breast cancer patients.

Locations(1)

New York-Presbyterian/Weill Cornell Medical Center

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06072807

Related Trials

Genomic Services Research Program

NCT025959571 location

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT052833304 locations

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

NCT070671381 location

Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)

NCT068852031 location

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

NCT06103864316 locations